Skip to main content
Fig. 2 | Alzheimer's Research & Therapy

Fig. 2

From: Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer’s disease and PET amyloid-positive patient identification

Fig. 2

MS_pT181 and MS_pT217 plotted against their corresponding unmodified counterparts. CSF concentration of MS_pT181 (a) and MS_pT217 (b) were plotted on their corresponding unmodified counterparts in the Montpellier cohort. Linear regression was computed in the AD and NAD populations (rho Spearman’s correlation coefficient and P value are indicated). Note that for MS_pT217, AD and NAD regression lines have slopes that are significantly different (slope ANCOVA comparison P < 0.001). The sample from the patient with brain metastasis (arrow) is clearly an outliner with low concentration of phosphorylated peptides and high concentration of non-phosphorylated peptides

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193